Concerns about the consistency of the post-marketing surveillance (PMS) for safety of medical devices is well known across the world. Only around 13% of post-marketing surveillance (PMS) clinical studies are completed on medical devices.[1] This is because new products or line extensions are launched frequently, even before full clinical trials of the parent device are […]